Cambridge Cognition: CNS Summit 2017

The CNS Summit takes place on the 16th-19th November in Boca Raton, Florida. The summit is a platform for fostering collaboration and innovation between the key players in cognitive technology. Cambridge Cognition will be presenting new data, speaking on the ‘Future of Cognition’ and participating in networking meetings.

 

Find us at the posters

Cambridge Cognition has been collaborating with Takeda on a Cognition Kit study to explore wearable devices as a means of conducting high frequency assessments for patients with major depressive disorder. Our Director of Research and Innovation, Dr Francesca Cormack, will be attending the conference and can tell you all about our exciting findings at the poster sessions.

 

Join us at the panel discussion

Alternatively, catch Dr Cormack at the panel discussion: ‘Technology and the Future of Cognition’ on Thursday 16th November. Dr Cormack will be speaking on the future of cognitive research, and the crucial role technology will play in advancing the field. Dr Cormack will be joined on the panel by other notable experts in technology and cognition:

  • Tom Insel, Co-Founder & President, Mindstrong
  • Richard Keefe, Co-Founder & CEO, NeuroCog Trials
  • Luca Pani, University of Miami, former CHMP & SAWP Member, European Medicines Agency
  • Paul Maruff, Chief Science Officer, Cosgate
  • Philip Harvey, Professor of Psychiatry & Behavioural Sciences, University of Miami Miller School of Medicine
Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions